Stockscreener 앱 받기
0.4169
6.19%
-0.0275
시간 외 거래:
.41
-0.0069
-1.66%
전일 마감가:
$0.4444
열려 있는:
$0.44
하루 거래량:
539.66K
Relative Volume:
1.03
시가총액:
$5.69M
수익:
$2.47M
순이익/손실:
$-24.73M
주가수익비율:
-0.099
EPS:
-4.213
순현금흐름:
$-20.36M
1주 성능:
-22.42%
1개월 성능:
-62.44%
6개월 성능:
-89.45%
1년 성능:
-96.94%
1일 변동 폭
$0.4101
$0.45
1주일 범위
$0.4101
$0.5553
52주 변동 폭
$0.4101
$14.80
VolitionRX Ltd Stock (VNRX) Company Profile
명칭
VolitionRX Ltd
전화
646 650 1351
주소
No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX
Compare VNRX vs TMO, DHR, NTRA, A, IDXX
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VNRX
VolitionRX Ltd
|
0.4169 | 6.07M | 2.47M | -24.73M | -20.36M | -4.213 |
TMO
Thermo Fisher Scientific Inc
|
629.27 | 232.03B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
218.85 | 151.78B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
332.03 | 46.82B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
159.00 | 44.14B | 7.23B | 1.41B | 1.09B | 4.979 |
IDXX
Idexx Laboratories Inc
|
556.93 | 43.00B | 4.45B | 1.10B | 1.06B | 13.59 |
VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-02-01 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2022-02-17 | 재개 | Cantor Fitzgerald | Overweight |
| 2021-03-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-05-16 | 개시 | Maxim Group | Buy |
| 2018-05-14 | 재확인 | The Benchmark Company | Buy |
| 2016-09-07 | 재확인 | Rodman & Renshaw | Buy |
| 2016-02-01 | 개시 | Rodman & Renshaw | Buy |
모두보기
VolitionRX Ltd 주식(VNRX)의 최신 뉴스
VolitionRX Ltd (VNRX) (Q2 2026) Earnings Call Highlights: Strate - GuruFocus
Benchmark reiterates Hold on VolitionRX stock amid cost cuts - Investing.com
Benchmark reiterates Hold on VolitionRX stock amid cost cuts By Investing.com - Investing.com Canada
VNRX Looks 97.6% Undervalued on GF Value™ - GuruFocus
Lagoda Investment discloses 14.0% VolitionRX (VNRX) stake in amended Schedule 13G - Stock Titan
Teleconferência de Resultados do 2º Trimestre de 2026 da VolitionRx (VNRX): Custos Caem à Medida que o Pipeline Nu.Q Avança - TradingKey
Conferencia de resultados del Q2 de 2026 de VolitionRx (VNRX): los costos caen a medida que avanza la cartera de desarrollo de Nu.Q - TradingKey
VolitionRx (VNRX) Q2 2026 Ergebniskonferenz: Kosten sinken bei Fortschritten der Nu.Q-Pipeline - TradingKey
Volitionrx Ltd earnings beat by $0.06, revenue fell short of estimates - Investing.com Canada
Transcript : VolitionRx Limited, Q2 2026 Earnings Call, Aug 14, 2026 - marketscreener.com
Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip - Investing.com Canada
VolitionRX Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
VolitionRx Limited Q2 2026 Earnings Call Summary - Yahoo Finance
VolitionRx Q2 Revenue Flat, but Licensing Talks and $5M Milestone Ahead - Minichart
VNRX|VolitionRX Ltd|Price:0.537|Chg%:-0.101 - TradingKey
VolitionRX: Q2 Earnings Snapshot - marketscreener.com
VolitionRx Q2 2026: Operating expenses fall 32% to $4.6 million - scanx.trade
Form 8K Volitionrx Ltd For: 13 August By Investing.com - Investing.com Nigeria
VolitionRx (VNRX) flags going concern risk amid $14M loss and NYSE plan - Stock Titan
VolitionRx Limited (NYSE: VNRX) doubles H1 2026 revenue and trims losses - Stock Titan
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update - Moomoo
Earnings To Watch: VolitionRX Ltd (VNRX) Q2 2026 -- GF Value Sees 3914% Upside - Yahoo Finance
VolitionRx Limited (VNRX) stock price, news, quote and history - Yahoo Finance UK
VolitionRx tests finger-prick sepsis prototype in patients - Investing.com Nigeria
VolitionRx tests finger-prick sepsis prototype in patients By Investing.com - Investing.com Australia
VolitionRx Limited Demonstrates Utility of Rapid Point-Of-Care Finger-Prick Test in Sepsis Patients - marketscreener.com
VolitionRx call will cover Q2 results and upcoming milestones - Stock Titan
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update - Yahoo Finance
5 Stocks To BUY HEAVY In Early August 2026 Cat Deeley (ii210v0TXj) - Mshale
VolitionRX Ltd (VNRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
VolitionRx issues 779,371 shares to Lind Global to meet convertible note obligations - Bitget
Volition's early liquid biopsy study detected 49 of 49 cancers - Stock Titan
VolitionRx publishes Capture-Seq paper targeting $36B market - scanx.trade
VolitionRx targets $3.8B sepsis market with Nu.Q NETs platform - scanx.trade
VolitionRX Ltd (VNRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VolitionRX Ltd (VNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VolitionRX Ltd (VNRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VolitionRX Ltd (VNRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
VolitionRX Ltd (VNRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
VNRX|VolitionRX Ltd|Price:0.890|Chg%:-0.110 - TradingKey
VolitionRX Ltd (VNRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
VolitionRX Ltd (VNRX) Balance Sheet - tradingkey.com
VolitionRX Ltd (VNRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VNRX|VolitionRX Ltd|Price:1.000|Chg%:-0.070 - TradingKey
TradingKey - TradingKey
VolitionRx Limited Amends Certificate of Incorporation: SEC Filing Details and XBRL Data 10 - Minichart
VOLITIONRX LTD SEC Filing (Jul 20, 2026) - Stock Titan
VolitionRx (VNRX) Stock Gets Fair Value Boost As Analysts Split On Nu.Q Execution - Yahoo Finance
VolitionRX (VNRX) Registration filing Summary - Quartr
VNRX Announces Sale of 3.31 Million Shares by Selling Stockholders - GuruFocus
VolitionRx (NYSE: VNRX) files to register 3.3M Lind-linked shares for resale - Stock Titan
VolitionRX Ltd (VNRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.06%
자본화:
|
볼륨(24시간):